Proretina Therapeutics SL is a Noáin, Spain-based biotech focused on developing therapeutics for retinal disorders. The company is studying the use of proinsulin to treat retinitis pigmentosa and has its first compound in an advanced preclinical stage. It plans to commence pharmacological development during 2011. Proretina is based in CEIN (Centro Europeo de Empresas e Innovación de Navarra) and operates a specialized laboratory in Madrid. The company currently employs seven people and intends to add three more professionals in the next year. Recently it closed a €380,000 equity financing that is subject to completion of the company’s project.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2010